Raquel Yahyaoui

Dr. Raquel Yahyaoui

Málaga Regional University Hospital
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
DMDavid M.S. McHugh
David M.S. McHugh
CCCynthia A. Cameron
Cynthia A. Cameron
JAJose E. Abdenur
Jose E. Abdenur
MAMahera Abdulrahman
Mahera Abdulrahman
OAOna Adair
Ona Adair
WZWendy M. Zakowicz
Wendy M. Zakowicz

Verified
Journal Article
Open access
PDF file
GLGerard Loeber
Gerard Loeber
DPDimitrios Platis
Dimitrios Platis
RZRolf H. Zetterström
Rolf H. Zetterström
SAShlomo Almashanu
Shlomo Almashanu
FBFrançois BOEMER
François BOEMER
Peter SchielenPeter Schielen
Peter Schielen
Neonatal screening (NBS) was initiated in Europe during the 1960s with the screening for phenylketonuria. The panel of screened disorders (“conditions”) then gradually expanded, with a boost in the late 1990s with the introduction of tandem mass spectrometry (MS/MS), making it possible to screen for 40–50 conditions using a single blood spot. The most recent additions to screening programmes (screening for cystic fibrosis, severe combined immunodeficiency and spinal muscular atrophy) were assisted by or realised through the introduction of molecular technologies. For this survey, we collected data from 51 European countries. We report the developments between 2010 and 2020 and highlight the achievements reached with the progress made in this period. We also identify areas where further progress can be made, mainly by exchanging knowledge and learning from experiences in neighbouring countries. Between 2010 and 2020, most NBS programmes in geographical Europe matured considerably, both in terms of methodology (modernised) and with regard to the panel of conditions screened (expanded). These developments indicate that more collaboration in Europe through European organisations is gaining momentum. We can only accomplish the timely detection of newborn infants potentially suffering from one of the many rare diseases and take appropriate action by working together.

1 June 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
Raquel YahyaouiRaquel Yahyaoui
Raquel Yahyaoui
IEI. Esteva
I. Esteva
JHJ. J. Haro-Mora
J. J. Haro-Mora
MAM. C. Almaraz
M. C. Almaraz
SMSonsoles Morcillo
Sonsoles Morcillo
FSF. Soriguer
F. Soriguer
Background: Transsexual persons afford a very suitable model to study the effect of sex steroids on uric acid metabolism. Design: This was a prospective study to evaluate the uric acid levels and fractional excretion of uric acid (FEUA) in a cohort of 69 healthy transsexual persons, 22 male-to-female transsexuals (MFTs) and 47 female-to-male transsexuals (FMTs). The subjects were studied at baseline and 1 and 2 yr after starting cross-sex hormone treatment. Results: The baseline levels of uric acid were higher in the MFT group. Compared with baseline, uric acid levels had fallen significantly after 1 yr of hormone therapy in the MFT group and had risen significantly in the FMT group. The baseline FEUA was greater in the FMT group. After 2 yr of cross-sex hormone therapy, the FEUA had increased in MFTs (P = 0.001) and fallen in FMTs (P = 0.004). In MFTs, the levels of uric acid at 2 yr were lower in those who had received higher doses of estrogens (P = 0.03), and the FEUA was higher (P = 0.04). The FEUA at 2 yr was associated with both the estrogen dose (P = 0.02) and the serum levels of estradiol-17β (P =0.03). In MFTs, a correlation was found after 2 yr of therapy between the homeostasis model assessment of insulin resistance and the serum uric acid (r = 0.59; P = 0.01). Conclusions: Serum levels of uric acid and the FEUA are altered in transsexuals as a result of cross-sex hormone therapy. The results concerning the MFT group support the hypothesis that the lower levels of uric acid in women are due to estrogen-induced increases in FEUA.

20 January 2017 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
TRTormod Rogne
Tormod Rogne
MTMyrte J. Tielemans
Myrte J. Tielemans
MCMary Foong-Fong Chong
Mary Foong-Fong Chong
CYChittaranjan S. Yajnik
Chittaranjan S. Yajnik
GKGhattu V. Krishnaveni
Ghattu V. Krishnaveni
KRKari R. Risnes
Kari R. Risnes
Vitamin B12 (hereafter referred to as B12) deficiency in pregnancy is prevalent and has been associated with both lower birth weight (birth weight <2,500 g) and preterm birth (length of gestation <37 weeks). Nevertheless, current evidence is contradictory. We performed a systematic review and a meta-analysis of individual participant data to evaluate the associations of maternal serum or plasma B12 concentrations in pregnancy with offspring birth weight and length of gestation. Twenty-two eligible studies were identified (11,993 observations). Eighteen studies were included in the meta-analysis (11,216 observations). No linear association was observed between maternal B12 levels in pregnancy and birth weight, but B12 deficiency (<148 pmol/L) was associated with a higher risk of low birth weight in newborns (adjusted risk ratio = 1.15, 95% confidence interval (CI): 1.01, 1.31). There was a linear association between maternal levels of B12 and preterm birth (per each 1-standard-deviation increase in B12, adjusted risk ratio = 0.89, 95% CI: 0.82, 0.97). Accordingly, B12 deficiency was associated with a higher risk of preterm birth (adjusted risk ratio = 1.21, 95% CI: 0.99, 1.49). This finding supports the need for randomized controlled trials of vitamin B12 supplementation in pregnancy.

18 October 2018 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
Stephan LobitzStephan Lobitz
Stephan Lobitz
PTPaul Telfer
Paul Telfer
ECElena Cela
Elena Cela
BABichr Allaf
Bichr Allaf
MAMichael Angastiniotis
Michael Angastiniotis
TEthe European Reference Network in Rare Haematological Diseases with the endorsement of EuroBloodNet
the European Reference Network in Rare Haematological Diseases with the endorsement of EuroBloodNet
Summary: Sickle Cell Disease (SCD) is an increasing global health problem and presents significant challenges to European health care systems. Newborn screening (NBS) forSCDenables early initiation of preventive measures and has contributed to a reduction in childhood mortality fromSCD. Policies and methodologies forNBSvary in different countries, and this might have consequences for the quality of care and clinical outcomes forSCDacross Europe. A two‐day Pan‐European consensus conference was held in Berlin in April 2017 in order to appraise the current status ofNBSforSCDand to develop consensus‐based statements on indications and methodology forNBSforSCDin Europe. More than 50SCDexperts from 13 European countries participated in the conference. This paper aims to summarise the discussions and present consensus recommendations which can be used to support the development ofNBSprogrammes in European countries where they do not yet exist, and to review existing programmes.

1 July 2012 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
GMGregg Marquardt
Gregg Marquardt
RCRobert J. Currier
Robert J. Currier
DMDavid M.S. McHugh
David M.S. McHugh
DGDimitar Gavrilov
Dimitar Gavrilov
MMMark J. Magera
Mark J. Magera
GHGary L. Hoffman
Gary L. Hoffman
To improve quality of newborn screening by tandem mass spectrometry with a novel approach made possible by the collaboration of 154 laboratories in 49 countries. A database of 767,464 results from 12,721 cases affected with 60 conditions was used to build multivariate pattern recognition software that generates tools integrating multiple clinically significant results into a single score. This score is determined by the overlap between normal and disease ranges, penetration within the disease range, differences between conditions, and weighted correction factors. Ninety tools target either a single condition or the differential diagnosis between multiple conditions. Scores are expressed as the percentile rank among all cases with the same condition and are compared to interpretation guidelines. Retrospective evaluation of past cases suggests that these tools could have avoided at least half of 279 false-positive outcomes caused by carrier status for fatty-acid oxidation disorders and could have prevented 88% of known false-negative events. Application of this computational approach to raw data is independent from single analyte cutoff values. In Minnesota, the tools have been a major contributing factor to the sustained achievement of a false-positive rate below 0.1% and a positive predictive value above 60%. Genet Med advance online publication 16 February 2012